22.11.2023 • News

EuroAPI Completes Acquisition of BianoGMP

EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides.

The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.

“We are delighted to welcome the talented people of Biano,” said Viviane Monges, EuroAPI’s CEO. “Biano has demonstrated a strong commitment to supporting clients with innovative oligonucleotide developments. I look forward to all that we will achieve together to sustainably meet clients’ and patients’ needs around the world through our complementarities.”

As planned, Biano will retain its corporate brand and become a EuroAPI company.

© nobeastsofierce - stock.adobe.co
© nobeastsofierce - stock.adobe.co

Company

Logo:

EuroAPI

15 rue Traversière
75012 Paris
France

Company contact







Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Virtual Event

Downstream Purification
Bioprocess Forum

Downstream Purification

Save the Date: November 21+25, 2025
Join leading scientists, process engineers, and biomanufacturing innovators for a two-day virtual event exploring the latest breakthroughs in downstream purification.

most read